Solamargine

Star0

DB12700InvestigationalSmall molecule

Solamargine has been used in trials studying the treatment of Actinic Keratosis.

Mechanism: Pharmacologically active on Myeloid zinc finger 1
Curator reviewed
Formula / weight: C₄₅H₇₃NO₁₅ · 868.0588 g/mol (avg)

Resolves to

Compound

UNII8KG991E7BNCAS20311-51-7ChEMBLCHEMBL443114ChEBI9185PubChem73611KEGGC10819

Structure

InChIKeyMBWUSSKCCUMJHO-ZGXDEBHDSA-NSMILES

C[C@H]1[C@H]2[C@H](C[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23C)O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](O)[C@H]3O)[C@H](O)[C@H]2O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](O)[C@H]2O)O[C@]11CC[C@@H](C)CN1

Targets

P28698MZF1

Transporters

P08183ABCB1

What you can answer from here — as of September 18, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1TransporterSubstrate / inhibitor direction, not just membership

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Solamargine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account